Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $32.5 million.

  • Phathom Pharmaceuticals' Non-Current Assets rose 145.83% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.5 million, marking a year-over-year increase of 145.83%. This contributed to the annual value of $18.2 million for FY2024, which is 10.81% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Non-Current Assets is $32.5 million, which was up 3.70% from $31.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Non-Current Assets high stood at $32.5 million for Q3 2025, and its period low was $3.3 million during Q1 2022.
  • Over the past 3 years, Phathom Pharmaceuticals' median Non-Current Assets value was $16.2 million (recorded in 2024), while the average stood at $17.6 million.
  • Data for Phathom Pharmaceuticals' Non-Current Assets shows a peak YoY skyrocketed of 288.41% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Non-Current Assets stood at $4.3 million in 2022, then soared by 281.81% to $16.4 million in 2023, then climbed by 10.81% to $18.2 million in 2024, then surged by 145.83% to $32.5 million in 2025.
  • Its last three reported values are $32.5 million in Q3 2025, $31.3 million for Q2 2025, and $29.3 million during Q1 2025.